Skip to content

A Study on the Scalability of potassium-enriched salt substitute "Prescriptions" by General Practitioners for Hypertensive Patients in Cold-Climate Regions

A Study on the Scalability of potassium-enriched salt substitute "Prescriptions" by General Practitioners for Hypertensive Patients in Cold-Climate Regions

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125657
Enrollment
Unknown
Registered
2026-05-29
Start date
2026-06-13
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Intervention group:1. National basic public health service project - health management service for hypertensive patients
2. General practitioners use paper potassium-enriched salt substitute "prescriptions" to "prescribe" potassium-enriched salt substitute to hypertensive patients alone
3. Provide potassium-enriched salt substitute related health education along with "prescription"
Control group:National basic public health service project - health management service for hypertensive patients

Sponsors

School of Public Health, Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with essential hypertension in the national basic public health service system: or self-reported history of hypertension; or are taking any antihypertensive drugs; or measured blood pressure thrice >140/90mmHg; 2. Meals at home at least 5 days a week; 3. >=18 years old and <=75 years old; 4. Can communicate normally with researchers; 5. Provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Participants or family members living with them report having severe kidney diseases (including: Polycystic Kidney Disease with autosomal dominant or autosomal recessive inheritance, a history of kidney transplantation, acute kidney injury, Chronic Kidney Disease (CKD) in stage G3b or G4 or G5, systemic lupus erythematosus nephritis or hyperkalemia, or a history of hyperkalemia. Definition of hyperkalemia: Serum potassium > 5.5 mmol/L, and pseudo-hyperkalemia is excluded; 2. The participant or any family member living with them is taking any potassium-sparing diuretic or potassium-supplementing drug; 3. Currently consuming low-sodium salt or participating in other dietary intervention programs; 4. Currently suffering from a serious and major illness; 5. One family member living together has participated in this study.

Design outcomes

Primary

MeasureTime frame
Proportion of people who purchased potassium-enriched salt substitute at least once in three months;

Secondary

MeasureTime frame
Proportion of people who used potassium-enriched salt substitute at least once in the three months following randomization;Systolic pressure;Diastolic pressure;Estimated 24-hour urinary sodium excretion;Estimated 24-hour urinary potassium excretion;KAP towards salt reduction;

Countries

China

Contacts

Public ContactZhang Jing

School of Public Health, Harbin Medical University

jing.zhang@hrbmu.edu.cn+86 138 1045 4698

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026